Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation

World Journal of Gastroenterology

Volumn 19, Issue 21, 2013, Pages 3255-3262

  Ponziani, Francesca Romana ^a   Annicchiarico, Eleonora Brigida ^a   Siciliano, Massimo ^a   D'Aversa, Francesca ^a   Pompili, Maurizio ^a   Gasbarrini, Antonio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Efficacy; Hepatitis C virus; Hepatitis C virus antiviral treatment; Liver cirrhosis; Liver transplantation; Safety; Sustained virological response

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; BRAIN DISEASE; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; INCIDENCE; INFLUENZA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE TRAUMA; NEUTROPENIA; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 84878616287     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i21.3255     Document Type: Article

References (39)

1. Berenguer M, Prieto M, Rayón JM, Mora J, Pastor M, Ortiz V, Carrasco D, San Juan F, Burgueño MD, Mir J, Berenguer J. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852-858[PMID: 11003634 DOI: 10.1053/ jhep.2000.1792]
2. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-1310[PMID: 16729298 DOI: 10.1002/hep.21176]
3. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29: 1311-1316[PMID: 10094980 DOI: 10.1002/hep.510290424]
4. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943[PMID: 22424438]
5. Bartosch B, Thimme R, Blum HE, Zoulim F. Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol 2009; 51: 810-820[PMID: 19545926 DOI: 10.1016/j.jhep.2009.05.008]
6. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010; 7: 448-458[PMID: 20628345 DOI: 10.1038/nrgastro.2010.100]
7. Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, Accadia L, Bombardieri G, Andriulli A. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46: 206-212[PMID: 17125876 DOI: 10.1016/ j.jhep.2006.08.020]
8. Fernández-Rodríguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rincón D, Rodriguez-Caravaca G, Bárcena R, Serra MA, Romero-Gómez M, Fernandez I, Garcia-Samaniego J, Fuente J, Solá R, Moreno-Otero R, Planas R. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol 2010; 105: 2164-2172; quiz 2173[PMID: 20700116 DOI: 10.1038/ajg.2010.294]
9. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-262[PMID: 16025497 DOI: 10.1002/hep.20793]
10. Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, García-Valdecasas JC, Navasa M, Rimola A, Rodés J. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396[PMID: 12927925 DOI: 10.1016/S0168-8278(03)00310-6]
11. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-355[PMID: 11965579 DOI: 10.1053/jlts.2002.31748]
12. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, Lampasi F, Tartaglione MT, Marsilia GM, Calise F, Cuomo O, Ascione A. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-465[PMID: 17196700 DOI: 10.1016/j.jhep.2006.10.017]
13. Berenguer M, Palau A, Aguilera V, Rayón JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-687[PMID: 18294165 DOI: 10.1111/ j.1600-6143.2007.02126.x]
14. Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, Bosch J, Forns X. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-1756[PMID: 17484872 DOI: 10.1053/ j.gastro.2007.03.041]
15. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669-674[PMID: 15030984 DOI: 10.1016/ j.jhep.2003.12.015]
16. Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, Rayón JM, Berenguer J. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12: 1067-1076[PMID: 16622844 DOI: 10.1002/ lt.20737]
17. Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF, Merli M, Strazzabosco M, Tisone G. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007; 46: 1009-1017[PMID: 17328985 DOI: 10.1016/ j.jhep.2006.12.017]
18. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699[PMID: 7560864 DOI: 10.1016/0168-8278(95)80226-6]
19. Program CTE. Available from: URL: http://ctep.cancer.gov
20. Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905-915[PMID: 12942451 DOI: 10.1053/jlts.2003.50166]
21. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, Rodes J. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-687[PMID: 11870384 DOI: 10.1053/ jhep.2002.31773]
22. Everson GT, Kulig CC. Antiviral therapy for hepatitis C in the setting of liver transplantation. Curr Treat Options Gastroenterol 2006; 9: 520-529[PMID: 17081485]
23. Firpi RJ, Clark V, Soldevila-Pico C, Morelli G, Cabrera R, Levy C, Machicao VI, Chaoru C, Nelson DR. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl 2009; 15: 1063-1071[PMID: 19718647 DOI: 10.1002/ lt.21784]
24. Kalambokis G, Manousou P, Samonakis D, Grillo F, Dhillon AP, Patch D, O'Beirne J, Rolles K, Burroughs AK. Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient. Transpl Int 2009; 22: 172-181[PMID: 18786149 DOI: 10.1111/ j.1432-2277.2008.00744.x]
25. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, Córdoba J, Herola A, Ascher N, Mir J, Berenguer J, Wright TL. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-684[PMID: 10782918 DOI: 10.1016/S0168-8278(00)80231-7]
26. Tisone G, Orlando G, Cardillo A, Palmieri G, Manzia TM, Baiocchi L, Lionetti R, Anselmo A, Toti L, Angelico M. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2006; 44: 702-709[PMID: 16473433 DOI: 10.1016/j.jhep.2005.11.047]
27. Orlando G, Manzia T, Baiocchi L, Sanchez-Fueyo A, Angelico M, Tisone G. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. Transpl Immunol 2008; 20: 43-47[PMID: 18773958 DOI: 10.1016/j.trim.2008.08.007]
28. Gurusamy KS, Tsochatzis E, Davidson BR, Burroughs AK. Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database Syst Rev 2010; (12): CD006573[PMID: 21154370 DOI: 10.1002/14651858.CD006573.pub2]
29. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586-1599[PMID: 16827859 DOI: 10.1111/j.1600-6143.2006.01362.x]
30. Walter T, Dumortier J, Guillaud O, Hervieu V, Paliard P, Scoazec JY, Boillot O. Rejection under alpha inter-feron therapy in liver transplant recipients. Am J Transplant 2007; 7: 177-184[PMID: 17227566 DOI: 10.1111/ j.1600-6143.2006.01590.x]
31. Stanca CM, Fiel MI, Kontorinis N, Agarwal K, Emre S, Schiano TD. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. Transplantation 2007; 84: 180-186[PMID: 17667809 DOI: 10.1097/01.tp.0000269609.08495.45]
32. Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, Farmer DG, Ghobrial RM, Yersiz H, Goldstein LI, Lassman CR, Busuttil RW. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004; 10: 859-867[PMID: 15237369 DOI: 10.1002/lt.20157]
33. Fernández I, Ulloa E, Colina F, Abradelo M, Jiménez C, Gimeno A, Meneu JC, Lumbreras C, Solís-Herruzo JA, Moreno E. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C. Liver Transpl 2009; 15: 948-955[PMID: 19642125 DOI: 10.1002/lt.21780]
34. Selzner N, Guindi M, Renner EL, Berenguer M. Immunemediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011; 55: 207-217[PMID: 21145865]
35. Fiel MI, Agarwal K, Stanca C, Elhajj N, Kontorinis N, Thung SN, Schiano TD. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl 2008; 14: 861-871[PMID: 18508382 DOI: 10.1002/lt.21447]
36. Cholongitas E, Samonakis D, Patch D, Senzolo M, Burroughs AK, Quaglia A, Dhillon A. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus. Transplantation 2006; 81: 488-490[PMID: 16477242 DOI: 10.1097/01.tp.0000196716.07188.c4]
37. Kontorinis N, Agarwal K, Elhajj N, Fiel MI, Schiano TD. Pegylated interferon-induced immune-mediated hepatitis postliver transplantation. Liver Transpl 2006; 12: 827-830[PMID: 16628699 DOI: 10.1002/lt.20706]
38. Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013; 58: 583-592[PMID: 23104162]
39. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444[PMID: 21898493 DOI: 10.1002/hep.24641]